Q-omics provides the consensus-scored STK17B profile across patient tissues and cancer cell-line models. STK17B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, STK17B is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, STK17B protein abundance shows 24,954 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where STK17B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STK17B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STK17B survival associations across molecular data types. STK17B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STK17B RNA expression–survival associations across cancer types. High STK17B expression shows unfavorable associations in KIRP, UVM and MESO, but favorable associations in LUAD, SKCM and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for STK17B RNA expression.
This table summarizes STK17B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for STK17B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STK17B shows lower tumor expression in KICH, LUSC and COAD and higher tumor expression in HNSC, KIRC and STAD. The HNSC box plot shows higher STK17B RNA expression in tumor versus normal tissue (log2 FC = +0.672, t-test p < 0.001).
This table shows molecular features associated with STK17B in patient tissues and cancer cell lines. In patient samples, STK17B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, STK17B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
